Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma
Top Cited Papers
- 5 February 2013
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (6) , 574-580
Abstract
Objective: To report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC). Methods: This was an open-label extension phase of a prospective, phase 1–2 trial (NCT00411619) in patients ≥3 years of age with SEGA associated with TSC. Patients received oral everolimus starting at 3 mg/m2 per day and subsequently titrated, subject to tolerability, to attain whole blood trough concentrations of 5–15 ng/mL. Change in SEGA volume, seizures, and safety assessments were the main outcome measures. Results: Of 28 patients enrolled, 25 were still under treatment at the time of analysis. Median dose was 5.3 mg/m2/day and median treatment duration was 34.2 months (range 4.7–47.1). At all time points (18, 24, 30, and 36 months), primary SEGA volume was reduced by ≥30% from baseline (treatment response) in 65%–79% of patients. All patients reported ≥1 adverse event (AE), mostly grade 1/2 in severity, consistent with that previously reported, and none led to everolimus discontinuation. The most commonly reported drug-related AEs were upper respiratory infections (85.7%), stomatitis (85.7%), sinusitis (46.4%), and otitis media (35.7%). No drug-related grade 4 or 5 events occurred. Conclusion: Everolimus therapy is safe and effective for longer term (median exposure 34.2 months) treatment of patients with TSC with SEGA. Classification of evidence: This study provides Class III evidence that everolimus, titrated to trough serum levels of 5–15 ng/mL, was effective in reducing tumor size in patients with SEGA secondary to TSC for a median of 34 months.Keywords
This publication has 23 references indexed in Scilit:
- The TSC1–TSC2 complex: a molecular switchboard controlling cell growthBiochemical Journal, 2008
- Regression of Pulmonary Lymphangioleiomyomatosis (PLAM)-associated Retroperitoneal Angiomyolipoma Post–Lung Transplantation With Rapamycin TreatmentThe Journal of Heart and Lung Transplantation, 2008
- Sirolimus Therapy in Tuberous Sclerosis or Sporadic LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Sirolimus Treatment for Pulmonary LymphangioleiomyomatosisAnnals of Internal Medicine, 2007
- SUBEPENDYMAL GIANT-CELL ASTROCYTOMASIN PEDIATRIC TUBEROUS SCLEROSIS DISEASENeurosurgery, 2007
- The Tuberous Sclerosis ComplexNew England Journal of Medicine, 2006
- Antitumoral Activity of Rapamycin in Renal Angiomyolipoma Associated With Tuberous Sclerosis ComplexAmerican Journal of Kidney Diseases, 2006
- Pathogenesis of Tuberous Sclerosis Subependymal Giant Cell Astrocytomas: Biallelic Inactivation ofTSC1orTSC2Leads to mTOR ActivationJournal of Neuropathology & Experimental Neurology, 2004
- Tuberous Sclerosis Complex Consensus Conference: Revised Clinical Diagnostic CriteriaJournal of Child Neurology, 1998